China SXT Pharmaceuticals, Inc. — Form 20-F Summary
Reporting period: Fiscal year ended March 31, 2019. The filing is an annual report, not a quarterly report for 2018 Q4; the source text does not provide a separate fourth-quarter financial statement.
Business context
China SXT is a British Virgin Islands holding company whose operations are conducted primarily in China through subsidiaries and a variable interest entity, Taizhou Suxuantang. The company researches, manufactures, markets and sells traditional Chinese medicine pieces in three categories: Advanced, Fine and Regular TCMP.
The company markets 19 Advanced TCMP products, more than 20 Fine TCMP products and approximately 427 Regular TCMP products. Its shares trade on the Nasdaq Capital Market under the symbol SXTC and began trading in January 2019.
Key financial metrics
| US$ unless stated otherwise | FY2019 | FY2018 | Change |
|---|---|---|---|
| Revenue | $7.012 million | $7.019 million | Flat; down $7,217 |
| Gross profit | $4.612 million | $3.401 million | Up 36% |
| Gross margin | 65.8% | 48.5% | Up 17.3 percentage points |
| Income from operations | $1.769 million | $1.632 million | Up 8% |
| Net income | $1.539 million | $1.188 million | Up 30% |
| Net margin | 21.9% | 16.9% | Up 5.0 percentage points |
| Basic and diluted EPS | $0.075 | $0.059 | Up 27% |
| Operating cash flow | $239,192 | $1.920 million | Down $1.681 million |
| Investing cash flow | $(610,085) | $(1.051) million | Lower outflow |
| Financing cash flow | $9.042 million | $(314,216) | IPO-driven increase |
Revenue mix shifted materially toward higher-margin products. Advanced TCMP revenue increased 52% to $3.632 million and represented approximately 52% of revenue, while Fine TCMP revenue increased 62% to $524,253. Regular TCMP revenue declined 34% to $2.856 million and represented approximately 41% of revenue.
Cash and cash equivalents were $9.131 million at March 31, 2019, compared with $560,252 at March 31, 2018. Including restricted cash, total cash, cash equivalents and restricted cash were $9.292 million. Total assets were $17.471 million, total liabilities were $6.363 million and shareholders’ equity was $11.108 million.
Current assets were $15.588 million versus current liabilities of $6.321 million, implying reported current liquidity of approximately 2.5 times. Accounts receivable increased to $4.181 million from $2.603 million, and the company recorded a $66,917 allowance for doubtful accounts.
Reported debt at March 31, 2019 was limited to $27,817 of short-term borrowing, $233,336 of notes payable, $41,706 of long-term payable and $2.483 million due to related parties. The related-party balances were unsecured, non-interest-bearing and payable on demand.
Material changes versus the prior comparable period
- Revenue was essentially unchanged, but product mix improved substantially as Advanced and Fine TCMP sales grew and Regular TCMP sales declined.
- Cost of revenue fell 34% to $2.400 million, primarily because higher-margin Advanced and Fine TCMP products represented a larger portion of sales and labor efficiency improved.
- Selling expense increased 213% to $1.605 million, including higher distribution expense and approximately $857,908 of advertising expense.
- The effective income tax burden declined after Taizhou Suxuantang qualified as a high-technology company; its applicable PRC income tax rate fell from 25% to 15% beginning in April 2018.
- Operating cash flow weakened sharply because of increased accounts receivable and changes in supplier and other working-capital balances, despite higher net income.
- The company completed its initial public offering and received approximately $6.49 million of net proceeds, contributing to the large increase in cash and equity.
- Management identified material weaknesses and significant deficiencies in internal control over financial reporting, including inadequate U.S. GAAP-capable accounting personnel, insufficient training and inadequate segregation of duties.
Outlook, contingencies and risks
Management expects to expand Advanced TCMP products, increase brand recognition, broaden its distribution network and develop additional products. The filing does not provide formal revenue, earnings or margin guidance.
The company states that cash, IPO proceeds and anticipated operating cash flows were expected to satisfy liquidity needs for at least 12 months. However, operating cash generation was modest relative to net income, the company acknowledged a need for additional financing, and substantially all cash was held in uninsured PRC bank accounts.
After the fiscal year-end, the company completed a May 2, 2019 private placement consisting of $15 million of senior convertible notes, warrants for 894,988 ordinary shares and four million pre-delivered ordinary shares used as security. The notes and warrants contain conversion, redemption, default, registration and dilution provisions.
In July 2019, investors issued event-of-default redemption notices. One investor demanded approximately $6.055 million, while another demanded approximately $8.263 million plus $222,698 of liquidated damages and late charges and at least $1.208 million for warrant repurchase. The company was negotiating forbearance and release agreements; the filing states that the outcome was uncertain. The obligations could materially impair liquidity, increase leverage and cause significant shareholder dilution.
In June 2019, the company committed up to $7.46 million to the Huangshan Panjie Investment LLP Fund, with $3.73 million paid in June and a second $3.73 million installment potentially due by October 31, 2019, subject to other limited partners’ contributions. The fund is intended to identify acquisition candidates in the TCM, pharmaceutical and biotechnology sectors.
Other important risks include dependence on a small number of customers, PRC regulatory and price-control requirements, renewal and maintenance of pharmaceutical permits and GMP certifications, supply-chain disruption, product liability without product-liability insurance, reliance on VIE contractual arrangements, PRC currency and capital-transfer controls, related-party transactions and guarantees, and potentially limited trading liquidity.
The company reported no material legal or administrative proceedings as of the filing date, but disclosed a subsequent demand from its former IPO underwriter seeking $925,000 and warrants as a claimed success fee related to the May 2019 private placement. Management characterized the claim as without merit and intended to defend it.
Facts investors should verify
- Confirm the filing period: the Form 20-F covers the fiscal year ended March 31, 2019, not a standalone 2018 Q4.
- Review the sustainability of the revenue mix shift and whether Advanced and Fine TCMP growth offsets the decline in Regular TCMP.
- Reconcile net income of $1.539 million with operating cash flow of only $239,192 and assess collectability of the $4.181 million accounts receivable balance.
- Determine the ultimate resolution, cash cost and dilution from the May 2019 convertible notes, warrants, pre-delivered shares and July 2019 default notices.
- Assess whether the company can fund its operating plan, potential $3.73 million fund contribution and debt obligations without additional dilutive financing.
- Monitor remediation of the disclosed internal-control material weaknesses and any subsequent auditor or SEC comments.
- Evaluate the legal enforceability and regulatory status of the VIE structure and the company’s ability to transfer cash from China to the offshore holding company.
- Verify renewal and continuing validity of the company’s pharmaceutical permits and GMP certifications, as well as the impact of PRC price controls and insurance-catalogue changes.